Mark Wilterding | VP, IR |
Michael Mussallem | Chairman & CEO |
Scott Ullem | Corporate VP & CFO |
Bernard Zovighian | Corporate VP, Transcatheter Mitral & Tricuspid Therapies |
Daveen Chopra | Corporate VP, Surgical Heart Valve Therapies |
Larry Wood | Corporate VP, Transcatheter Aortic Valve Replacement |
Robert Marcus | JPMorgan Chase & Co. |
Larry Biegelsen | Wells Fargo |
Vijay Kumar | Evercore ISI |
Matthew Miksic | Barclays |
Joanne Wuensch | Citibank |
Chris Pasquale | Nephron |
Cecila Furlong | Morgan Stanley |
Travis Steed | Bank of America |
Joshua Jennings | Cowen |
Adam Maeder | Piper Sandler |
Richard Newitter | Truist Securities |
Greetings, and welcome to the Edwards Lifesciences Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions]Please note, this conference is being recorded.
I will now turn the conference over to our host, Mark Wilterding, Senior Vice President of Investor Relations and Treasurer. Thank you.
You may begin.